Howard M. Sandler
Cedars-Sinai Medical Center
CancerInternal medicineRadiologyUrologySurgeryOncologyRandomized controlled trialHazard ratioExternal beam radiotherapyProstateBrachytherapyAndrogen deprivation therapyProstatectomyProstate cancerProstate-specific antigenGynecologyNuclear medicineProportional hazards modelRadiation therapyMedicine
535Publications
96H-index
25.9kCitations
Publications 524
Newest
#1Christopher U Jones (Sutter Medical Center)
#2Stephanie L. PughH-Index: 23
Last. J.M. Longo (MCW: Medical College of Wisconsin)H-Index: 5
view all 22 authors...
PURPOSE For men with localized prostate cancer, NRG Oncology/Radiation Therapy Oncology Group (RTOG) 9408 demonstrated that adding short-term androgen deprivation therapy (ADT) to radiation therapy (RT) improved the primary endpoint of overall survival (OS) and improved disease-specific mortality (DSM), biochemical failure (BF), local progression, and freedom from distant metastases (DM). This study was performed to determine whether the short-term ADT continued to improve OS, DSM, BF, and freed...
Source
#1E. Anderson (Cedars-Sinai Medical Center)
#2Sungjin KimH-Index: 26
Last. Mitchell KamravaH-Index: 19
view all 0 authors...
Source
#1Jinbing BaiH-Index: 12
#2Stephanie L. PughH-Index: 23
Last. Jeff M. MichalskiH-Index: 73
view all 20 authors...
Source
#1John R. David (Cedars-Sinai Medical Center)H-Index: 90
#2Michael Luu (Cedars-Sinai Medical Center)H-Index: 12
Last. Mitchell Kamrava (Cedars-Sinai Medical Center)H-Index: 19
view all 6 authors...
Abstract Introduction The addition of brachytherapy (BT) in high risk prostate cancer is supported by Level 1 evidence. Whether all high risk patients benefit from BT to the same extent is unknown. The National Cancer Database (NCDB) was used to investigate overall survival (OS) differences between GS 8 and 9-10 treated with external beam radiation (EBRT) only or BT +/- EBRT. Materials and Methods We included localized prostate adenocarcinoma definitively treated with radiation between 2004-2014...
Source
#1Diana J. Lu (Cedars-Sinai Medical Center)H-Index: 6
#2Benjamin King (Cedars-Sinai Medical Center)
Last. Katelyn M. Atkins (Cedars-Sinai Medical Center)H-Index: 4
view all 6 authors...
Source
#1Eric M. AndersonH-Index: 5
#2Sungjin KimH-Index: 26
Last. Mitchell KamravaH-Index: 19
view all 4 authors...
Source
#1Rahul Khairnar (UMB: University of Maryland, Baltimore)H-Index: 7
#2Stephanie L. PughH-Index: 23
Last. Mark V. Mishra (UMB: University of Maryland, Baltimore)H-Index: 14
view all 23 authors...
PURPOSE The Expanded Prostate Cancer Index Composite (EPIC) is the most commonly used patient reported outcome (PRO) tool in prostate cancer (PC) clinical trials, but health utilities associated with the different health states assessed with this tool are unknown, limiting our ability to perform cost-utility analyses. This study aimed to map EPIC tool to EuroQoL-5D-3L (EQ5D) to generate EQ5D health utilities. METHODS AND MATERIALS This is a secondary analysis of a prospective, randomized non-inf...
Source
#1Felix Y. Feng (UCSF: University of California, San Francisco)H-Index: 78
#2Huei-Chung HuangH-Index: 3
Last. Phuoc T. Tran (Johns Hopkins University)H-Index: 50
view all 28 authors...
Importance Decipher (Decipher Biosciences Inc) is a genomic classifier (GC) developed to estimate the risk of distant metastasis (DM) after radical prostatectomy (RP) in patients with prostate cancer. Objective To validate the GC in the context of a randomized phase 3 trial. Design, Setting, and Participants This ancillary study used RP specimens from the phase 3 placebo-controlled NRG/RTOG 9601 randomized clinical trial conducted from March 1998 to March 2003. The specimens were centrally revie...
7 CitationsSource
#1Jun Gong (Cedars-Sinai Medical Center)H-Index: 11
#2Edwin M. Posadas (Cedars-Sinai Medical Center)H-Index: 36
Last. Robert A. Figlin (Cedars-Sinai Medical Center)H-Index: 97
view all 11 authors...
DNA-damage repair (DDR) pathway mutations can sensitize cancer cells to a class of cancer therapeutics known as PARP inhibitors. Given that DDR alterations can be found in up to one-third of advanced prostate cancers, PARP inhibitors have recently been established in treatment-refractory settings. We provide an updated review of the clinical data supporting the 4 PARP inhibitors that have undergone the most investigation thus far in metastatic castrate-resistant prostate cancer (mCRPC). Two of t...
1 CitationsSource
#1Rahul Khairnar (Genentech)
#2Howard M. Sandler (Cedars-Sinai Medical Center)H-Index: 96
Last. Mark V. Mishra (UMB: University of Maryland, Baltimore)H-Index: 14
view all 20 authors...
60Background: Mapping algorithms informing economic evaluations are often derived using baseline data from clinical trials. It is unclear if these algorithms can predict health utilities accurately...
Source